Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2022 - 12 - 15
点击次数: 0
Positions: CEO
Company: RedCloud Bio
个人简介:
Before joining RedCloud Bio, Dr. Mai-Jing Liao was a co-founder of HBM Holdings Ltd. (02142.hk), in the roles of Executive Director of the Board, Chief Commercial Officer and Chief Business Officer. He also served in multiple roles in marketing, strategic marketing and business development of Johnson & Johnson’s Centocor and Xi’an Janssen, where he was responsible for the launch and marketing of many innovative drugs for immunological diseases and cancers.Dr. Liao received his MBA from Johnson School at Cornell University and his Ph.D. from The University of North Carolina at Chapel Hill. Dr. Liao was a postdoctoral fellow in Dr. Robert Weinberg’s laboratory at Whitehead Institute for Biomedical Research, MIT.
发布时间: 2022 - 12 - 15
点击次数: 0
Positions: SVP &CCO
Company: JW Therapeutics Co., Ltd.
个人简介:
Alex Wu, Chief Commercial Officer (CCO) and Senior Vice President (SVP)  of JW Therapeutics, has accelerated first product commercialization. Alex has 28 years’ experience in portfolio commercial operation, strategy planning and management in healthcare industry. Before joining JW Therapeutics, Alex was Vice President and Managing Director of Hospital Specialty Business in MSD China, during which he has led plenty of products overriding global market. Prior to that, he also served with key position in Baxter, J&J and other MNCs. He created innovative commercial model and achieved outstanding outcome. Alex has obtained his EMBA (Executive Master of Business Administration) degree from China Europe International Business School (CEIBS).
发布时间: 2022 - 12 - 15
点击次数: 0
Positions: CBO
Company: StemiRNA Therapeutics
个人简介:
张继国先生现任斯微生物首席商务官,在加入斯微生物之前,张继国先生先后在药明生物担任疫苗业务副总裁,药明康德担任战略副总裁。张继国先生还曾在GSK疫苗总部担任新兴市场副总裁兼中国管理委员会成员。他的职业生涯从销售开始,曾在辉瑞中国和西安杨森任职,先后担任产品经理,新业务发展负责人,战略市场总监,在战略、业务发展、营销管理等方面积累了丰富经验。张继国先生也是虹博基因的创始人,曾以优异的成绩毕业于北京大学医学部以及北京大学国家发展研究院。
发布时间: 2022 - 12 - 15
点击次数: 0
Positions: CIO (Greater China)
Company: CMS
个人简介:
Dr. Fei Jiang is the Chief Investment Officer (Greater China) of CMS Group (0867.HK). He’s in charge of CMS’ strategic investment as well as business development in Greater China Region.Dr. Jiang got his Ph.D. degree in chemical engineering from Syracuse University, New York at 2006, after receiving his bachelor degree, also in chemical engineering, from East China University of Science and Technology, Shanghai at 1998. After graduation, he joined Cell Genesys at South San Francisco, California, to develop cancer cell-based immunotherapy products, and AlphaVax Inc. at Research Triangle Park, North Carolina, to develop RSV and CMV vaccines. Dr. Jiang returned to China and joined in 3SBio (1530.HK) at 2010. He served as R&D Manager, and later R&D Director till 2013. He shifted his role to BD Director since 2013, and took care of business development and strategic alliance management for 3SBio. He joined in healthcare investment business since 2017, and served as the Executive Director of Guijing Capital and Sinopharm Capital, and the Managing Director of Aplus Capital successively.